An independent virtual symposium held during ISTH 2021 – Practical considerations around the use of TPO-RAs in ITP

Dr Hillary Maitland is an Associate Professor of Medicine in the division of Hematology Oncology at the University of Virginia Emily Couric Clinical Cancer Center in Charlottesville Virginia. Her clinical focus is in the treatment of patients with non-malignant hematologic conditions, particularly those with disorders of hemostasis. She leads the hospital’s quality coalition for anticoagulation and thrombosis prevention. Her research focus is on quality and safety of anticoagulant therapies, treatment and prevention of thrombosis.

Dr Hanny Al-Samkari is an Assistant Professor of Medicine at Harvard Medical School and clinical investigator in the Massachusetts General Hospital (MGH) Division of Hematology. He also serves as the Associate Director of the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence. His clinical and research interests are in hemostasis, thrombosis, and hemolysis, with focuses in immune thrombocytopenia, HHT, anti-angiogenic therapeutics, and hereditary hemolytic anemias. He also does research into novel indications for the thrombopoietin receptor agonists. He currently serves as PI for several clinical trials in these areas.

Waleed Ghanima is Head of Research and a Consultant Haematologist at Østfold Hospital, Norway and a Professor in the Institute of Clinical Medicine, University of Oslo, Norway. Dr Ghanima gained his medical degree from the College of Medicine, University of Baghdad, Iraq. He joined Østfold Hospital in 2001, becoming a Consultant Haematologist in 2004, assuming his current position as Head of Research in 2014. Professor Ghanima’s main research field is venous thrombosis and immune thrombocytopenia (ITP). He has published more than 120 articles in national and international peer-reviewed journals.